Compare Herantis Pharma Oyj with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.26%
0%
11.26%
6 Months
-6.16%
0%
-6.16%
1 Year
42.92%
0%
42.92%
2 Years
10.6%
0%
10.6%
3 Years
2.94%
0%
2.94%
4 Years
-4.47%
0%
-4.47%
5 Years
-32.87%
0%
-32.87%
Herantis Pharma Oyj for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
3.98%
EBIT to Interest (avg)
-5.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
1.18%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-29.18
EV to EBIT
-7.83
EV to EBITDA
-7.83
EV to Capital Employed
-50.10
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.40
-5.00
-28.00%
Interest
0.40
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.60
-4.90
-34.69%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -34.69% vs -1,733.33% in Dec 2024
About Herantis Pharma Oyj 
Herantis Pharma Oyj
Pharmaceuticals & Biotechnology
Herantis Pharma Oyj is a Finland-based drug development Company with the purpose to evolve the treatment of diseases with unmet clinical needs, such as Parkinson’s disease and secondary lymphedema. The Company's product development portfolio includes: CDNF for Parkinson’s disease, Lymfactin in breast cancer-associated secondary lymphedema and Non-invasive xCDNF in neurodegenerative diseases.
Company Coordinates 
Company Details
Bertel Jungin aukio 1 , ESPOO None : 02600
Registrar Details






